Mycobacterial fractionated compounds require a functional immune system for efficacy. They have a non-specific immune stimulatory primarily on cell-mediated immune mechanisms and macrophage activation. Interleukin-1 release from macrophages is thought to be the primary mediator for their actions.
While there has been very limited experience using mycophenolate in veterinary medicine, it potentially could be useful in the treatment of a variety of autoimmune diseases, including immunemediated hemolytic anemia (IMHA), myasthenia gravis, glomerulonephritis, and pemphigus foliaceous. While mycophenolate has been suggested for use in treating inflammatory bowel disease in dogs, the drug’s primary adverse effects in dogs are gastritis, diarrhea, and intestinal inflammation. Mycophenolate is also used in anti-rejection protocols for organ transplants in animals. mycophenolate mofetil 639 In humans, although it is used “off label” for a variety of autoimmune disease indications, the drug is only labeled for use to prevent transplant rejection.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
必須封閉確切菌種、細胞壁分餾、產品代碼、商品、強度、容器、賦形劑、物種、適應症、途徑、療程、診斷、免疫狀態、繁殖狀態、法域與雙向交互作用。
DRUGAPI 劑量審查引用的獸醫官方標示（各標示只適用於其產品、物種與法域，不可互換）
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。